Head-to-head
Semaglutide vs AOD-9604
Side by side from the same data: half-life, evidence tier, research amounts, common schedule, and every decay curve on one chart.
How they differ
A plain-language read of what actually sets them apart. Reference only, not medical advice.
The same rough goal — weight — but almost nothing else in common. AOD-9604 is a growth-hormone fragment whose two human trials were pills, one failing at every dose, so its injected use comes from the community and it's gone in under half an hour. Semaglutide is a weekly gut-hormone shot that lasts about a week and has a large weight trial behind it.
Side by side
Every figure is drawn from this site's own compound data — the same numbers on each compound's page.
| Measure | Semaglutide | AOD-9604 |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence | A · Tested in people | B · Some human use |
| Route | Subcutaneous | Oral |
| Half-life | 168 h | 0.4 h |
| Typical vial | 3 / 5 / 10 mg | 5 / 10 mg |
| Research amount | 0.25–2.4 mg | 250–500 mcg |
| Common schedule | Once a week | Every day |
| Cycle / break | Titrated | — |
| Studied for | Metabolism and weight | Metabolism and weight |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Every compound on one chart — something the single-compound pages cannot show.
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.